An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules

Cancer Gene Therapy

Volumn 6, Issue 3, 1999, Pages 254-262

  Haas, Claudia ^a   Herold Mende, Christel ^b   Gerhards, Roswitha ^c   Schirrmacher, Volker ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Bispecific antibody; Cancer vaccine; Newcastle disease virus; T cell costimulation; Tumor associated antigen

Indexed keywords

BISPECIFIC ANTIBODY; CANCER VACCINE; CD69 ANTIGEN; INTERLEUKIN 2 RECEPTOR; LEUKOCYTE ANTIGEN; T LYMPHOCYTE ANTIGEN;

ARTICLE; BIOLOGICAL MODEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; DRUG EFFECT; GENE THERAPY; GENETICS; HUMAN; HYBRIDOMA; METABOLISM; METHODOLOGY; T LYMPHOCYTE; TIME;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GENE THERAPY; HUMANS; HYBRIDOMAS; MODELS, BIOLOGICAL; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0033128269     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700048     Document Type: Article

References (46)

1. Janeway CH, Bottomly K. Signals and signs for lymphocyte responses. Cell. 1994;76:275-285.
2. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992;71: 1093-1102.
3. + T cells by B7-transfected melanoma cells. Science. 1993;259:368-370.
4. Dranoff G, Jaffee E, Lanzenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Nail Acad Sci USA. 1993;90:3539-3543.
5. Khazaie K, Prifti S, Beckhove P, et al. Persistence of dormant tumor-cells in the bone marrow of tumor-cell-vaccinated mice correlates with long-term immunological protection. Proc Natl Acad Sci USA. 1994;91:7430-7434.
6. Cayeux S, Beck C, Aicher A, Dörker B, Blankenstein T. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur J Immunol. 1995;25:2325-2331.
7. Habicht A, Lindauer M, Galumbacher P, et al. Development of immunogenic colorectal cancer cell lines for vaccination: expression of CD80 (B7.1) is not sufficient to restore impaired primary T cell activation in vitro. Eur J Cancer. 1995;31A:2396-2402.
8. Walunas TL, Lenschow D, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1:405-413.
9. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996; 271:1734-1736.
10. Cassel WA, Garret R. Newcastle disease virus as an antineoplastic agent. Cancer. 1965;18:863.
11. Csatary L, Eckhardt S, Kukosza I. Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev. 1993;17:619-627.
12. von Hoegen P, Weber E, Schirrmacher V. Modification of tumor cells by a low dose of Newcastle disease virus: augmentation of the tumor-specific T cell response in the absence of an anti-viral response. Eur J Immunol. 1988;18: 1159-1166.
13. Heicappell R, Schirrmacher V, von Hoegen P, Ahlert T, Appelhans B. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. Int J Cancer. 1986;37:569-577.
14. Plaksin D, Progador A, Vadai E, Feldman M, Schirrmacher V, Eisenbach L. Effective antimetastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV). Int J Cancer. 1994;59:796-801.
15. Ertel C, Millar NS, Emmerson PT, Schirrmacher V, von Hoegen P. Viral hemagglutinin augments peptide-specific cytotoxic T-cell responses. Eur J Immunol. 1993;23:2592-2596.
16. von Hoegen P, Zawatzky R, Schirrmacher V. Modification of tumor cells by a low dose of Newcastle disease virus: potentiation of tumor specific cytolytic T cell activity via induction of interferon-α/β. Cell Immunol. 1990;126:80-90.
17. Schirrmacher V, Haas C, Ertel C. Virus potentiation of tumor vaccine T cell stimulatory capacity requires cell surface binding but not infection. Clin Cancer Res. 1997;3: 1135-1148.
18. Liebrich W, Schlag P, Manasterski M, et al. In vitro and clinical characterization of a Newcastle disease virus-modified autologous tumor cell vaccine for treatment of colorectal cancer patients. EurJ Cancer. 1991;27:703-710.
19. Pomer S, Schirrmacher V, Thiele R, Löhrke H, Brkovic D, Staehler G. Tumor response and 4 year survival data of patients with advanced renal cell carcinoma treated with autologous tumor vaccine and subcutaneous rIL-2 and IFN-α. Int J Oncol. 1995;6:947-954.
20. Ockert D, Schirrmacher V, Beck N, et al. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res. 1996;2:21-28.
21. Ahlert T, Sauerbrei W, Bastert G, et al. Tumor cell number and viability as quality and efficacy parameters of autologous virus modified cancer vaccines. J Clin Oncol. 1997;15:1354-1366.
22. Knapp-Dorkin B, Rieber EP. Leukocyte Typing III: White Cell Differentiation Antigens. New York: Oxford University Press; 1989.
23. Iorio RM, Nicholson PM, Bratt MA. Genetic variation within a neutralizing domain of the haemagglutinin-neuraminidase glycoprotein of Newcastle disease virus. J Gen Virol. 1986;67:1393-1402.
24. Kenney S, Pagano IS. Viruses as oncolytic agents: a new age for "therapeutic" viruses. J Natl Cancer Inst. 1994;86: 1185-1186.
25. Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R, Ertel C. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther. 1999;6:63-73.
26. Schlag P, Manasterski M, Gerneth TH, et al. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer: first evaluation of clinical response of a phase-II trial. Cancer Immunol Immunother. 1992;35:325-330.
27. Möbus V, Horn S, Stöck M, Schirrmacher V. Tumor cell vaccination for gynecological tumors. Hybridoma. 1993;12: 543-547.
28. Liu Y, Janeway C, Jr. Cells that present both specific ligand and costimulatory activity arc the most efficient inducers of clonal expansion of normal CD4 T cells. Proc Natl Acad Sci USA. 1992;89:3845-3849.
29. Tongh DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science. 1993;272:1947-1950.
30. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 1994;264:961-965.
31. Schirrmacher V, von Hoegen P. Importance of tumor cell membrane integrity and viability for CTL activation by cancer vaccines. Vaccine Res. 1993;2:183-196.
32. Weiner LM, Clark JI, Ring DB, Alpaugh RK. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB2 and FcγRIII. J Hematother. 1995; 4:453-456.
33. Michon J, Perdereau B, Brixy F, Moutel S, Fridman WH, Teillaud JL. In vivo targeting of human neuroblastoma xenograft by anti-GD2/anti-FcγRI (CD64) bispecific antibody. Eur J Cancer. 1995;31 A:631-636.
34. De Gast GL, van Houten AA, Haagen IA, et al. Clinical experience with CD3×CD19 bispecific antibodies in patients with B cell malignancies. J Hematother. 1995;4:433-437.
35. 2. J Natl Cancer Inst. 1993;85:1003-1004.
36. Kroesen BJ, Janssen RA, Buter J, et al. Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunological aspects. J Hematother. 1995;4: 409-414.
37. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T-cell responses to antigen. Annu Rev Immunol. 1993;11:191-212.
38. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell. 1994;76:241-251.
39. Umansky V, Rocha M, Krüger A, von Hoegen P, Schirrmacher V. In situ activated macrophages are involved in host resistance to lymphoma metastasis by production of nitric oxide. Int J Oncol. 1995;7:33-40.
40. Rocha M, Krüger A, van Rooijen N, Schirrmacher V, Umansky V. Liver endothelial cells participate in T cell-dependent host resistance to lymphoma metastasis by production of nitric oxide in vivo. Int J Cancer. 1995;63: 405-411.
41. Renner C, Ohnesorge S, Held G, et al. T cells from patients with Hodgkin's disease have a defective T cell receptor ζ chain expression that is reversible by T cell stimulation with CD3 and CD28. Blood. 1996;88:236-241.
42. Renner S, Bauer S, Sahin U, et al. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model. Blood. 1996;87:2930-2937.
43. Schirrmacher V, Beckhove P, Krüger A, et al. Effective immune rejection of advanced metastasized cancer. Int J Oncol. 1995;6:505-521.
44. Guo YJ, Che XY, Shen F, et al. Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies. Nat Med. 1997;3:451-455.
45. Lord EM, Frelinger JG. Tumor immunotherapy: cytokines and antigen presentation. Cancer Immunol Immunother. 1998;46:75-81.
46. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:238-332.